Last reviewed · How we verify
CBT-004
CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.
CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Solid tumors (specific antigen target and indication under investigation in Phase 2).
At a glance
| Generic name | CBT-004 |
|---|---|
| Sponsor | Cloudbreak Therapeutics, LLC |
| Drug class | T cell engager / Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CBT-004 functions as a bispecific antibody or T cell-engaging therapeutic that bridges T cells and tumor cells, enabling direct cytotoxic killing. By engaging both CD3 on T cells and a tumor-associated antigen, the drug facilitates immune synapse formation and T cell activation against cancer cells. This approach leverages the patient's own immune system to target malignant cells.
Approved indications
- Solid tumors (specific antigen target and indication under investigation in Phase 2)
Common side effects
- Cytokine release syndrome
- T cell activation-related toxicity
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBT-004 CI brief — competitive landscape report
- CBT-004 updates RSS · CI watch RSS
- Cloudbreak Therapeutics, LLC portfolio CI